0324 Asher ECP
BioCentury & Getty Images

Emerging Company Profile

Asher Bio: aiming cytokine therapies at specific immune cells

Emerging Company Profile: Asher Bio engineering cytokine specificity with Third Rock-led $55 million series A

Asher Biotherapeutics launches with a Third Rock-led $55 million series A and a platform to improve the safety and efficacy of cytokines by requiring binding to two targets on a single immune cell.

Mar 25, 2021 | 11:06 PM GMT

Asher Bio emerged from stealth Tuesday with

Read the full 763 word article

How to gain access

Continue reading with a
two-week free trial.